Tissue targeted antigenic activation of the immune response to treat cancers
The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.
1. A method for treating a human patient having a melanoma situated in the skin or skin tissue, the method comprising:
administering to the patient an effective amount of a medicament to treat the melanoma, the medicament comprising whole killed cells of only one microbial pathogen, wherein the microbial pathogen is Staphylococcus aureus,
wherein the whole killed cells are whole cells wherein the whole killed cells are present in an amount effective to elicit an immune reaction effective to treat the melanoma.
2. The method according to claim 1 , wherein the method comprises administering the medicament in successive doses given at a dosage interval of between one hour and one month, over a dosage duration of at least two weeks.
3. The method according to claim 2 , wherein the method comprises administering the medicament intradermally or subcutaneously in a dose so that each dose is effective to cause a localized inflammatory immune response at an administration site.
4. The method according to claim 3 , wherein the method comprises administering the medicament in a manner such that visible localized inflammation at the administration site occurs within 1 to 48 hours.
5. The method according to claim 1 , wherein the method comprises administering the medicament intradermally or subcutaneously.
6. The method according to claim 2 , wherein the method comprises administering the medicament intradermally or subcutaneously.
7. The method according to claim 1 , wherein the method comprises orally administering the medicament.
8. The method according to claim 1 , wherein the method further comprises administering to the patient an effective amount of an anti-inflammatory agent.
9. The method according to claim 8 , wherein the anti-inflammatory agent is an NSAID.
10. The method of claim 1 , wherein the method further comprises diagnosing the patient as having suffered from a prior pathogenic exposure to the microbial pathogen.
11. The method of claim 1 , wherein the patient is a patient that has been diagnosed as having suffered from a prior pathogenic exposure to the microbial pathogen.
12. A method for selecting an antigenic composition and treating a human patient, comprising:
diagnosing the patient as having a melanoma situated in the skin or skin tissue;
selecting an antigenic composition comprising whole killed cells of only one microbial pathogen, wherein the microbial pathogen is Staphylococcus aureus ; and,
administering the antigenic composition to the patient to elicit an immune reaction to treat the melanoma,
wherein the whole killed cells are whole cells wherein the whole killed cells are present in an amount effective to elicit an immune reaction effective to treat the melanoma.
13. The method of claim 12 , wherein the method comprises administering the antigenic composition by subcutaneous injection, intradermal injection or oral administration.
14. The method of claim 13 , wherein the method comprises administering the antigenic composition by subcutaneous or intradermal injection in a dose effective to produce a localized skin immune response at a site of administration.
15. The method according to claim 14 , wherein the method comprises administering the antigenic composition so that visible localized inflammation at the administration site occurs within 1 to 48 hours.
16. The method according to claim 12 , wherein the method comprises administering the antigenic composition in successive doses given at a dosage interval of between one hour and one month, over a dosage duration of at least two weeks.
17. The method according to claim 13 , wherein the method comprises administering the antigenic composition in successive doses given at a dosage interval of between one hour and one month, over a dosage duration of at least two weeks.
18. The method according to claim 14 , wherein the method comprises administering the antigenic composition in successive doses given at a dosage interval of between one hour and one month, over a dosage duration of at least two weeks.
19. The method according to claim 1 , wherein the administering is at a site distant from location of the melanoma.
20. The method according to claim 1 , wherein the administering results in a reduction in volume of the melanoma.
21. The method according to claim 5 , wherein the administering is at a site distant from location of the melanoma.
22. The method according to claim 21 , wherein the administering results in a reduction in volume of the melanoma.
23. The method according to claim 12 , wherein the administering is at a site distant from location of the melanoma.
24. The method according to claim 12 , wherein the administering results in a reduction in volume of the melanoma.
25. The method of claim 12 , wherein the method comprises administering the antigenic composition by subcutaneous injection or intradermal injection at a site distant from location of the melanoma.
26. The method according to claim 25 , wherein the administering results in a reduction in volume of the melanoma.
27. The method according to claim 1 , wherein the medicament comprises whole killed cells of the only one microbial pathogen as the sole active agent effective for treating the melanoma.
28. The method according to claim 12 , wherein the antigenic composition comprises whole killed cells of the only one microbial pathogen as the sole active agent effective for treating the melanoma.